Vertex Pharmaceuticals on Wednesday received expanded approval from the Food and Drug Administration for its cystic fibrosis drug, Kalydeco.
While the FDA originally approved Kalydeco to treat 10 rare gene mutations associated with the disease, the drug now can be used to treat 33 mutations.
Cystic fibrosis patients take Kalydeco — in a tablet or oral granule form — twice a day for improved lung function, among other benefits.
More articles on supply chain:
Viewpoint: Why healthcare needs more 'me too' drugs
FDA approves virtual reality rehab device for stroke, brain injury patients
Magellan vein-based blood tests underreported lead levels, says health officials